MedPage Today) — The FDA added a boxed warning to delandistrogene moxeparvovec (Elevidys) gene therapy for Duchenne muscular dystrophy and changed the indication of the drug after reports of fatal liver injury emerged, the agency announced Friday…
Gene Therapy Gets FDA’s Strongest Warning After Fatal Liver Injuries

Leave a Comment Leave a Comment
